Early Phase 1 N=27 Human Amniotic Membrane to Decrease Post Operative Atrial Fibrillation
Atrial Fibrillation
Primary: Number of Participants With Adverse Events — 0; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Early Phase 1 N=52 A Phase I Study to Evaluate LSALT Peptide
None - Study is to Determine Safety in Healthy Participants
Primary: Safety Evaluation — 3; 1; 6; 2 participants
Early Phase 1 N=22 Effects of Drugs on Responses to Brain and Emotional Processes
Autism Spectrum Disorder · Healthy
Primary: Change in Responses to Affective Touch — 3.01; 4.06 units on a scale
Early Phase 1 N=124 Topical Tranexamic Acid Use on Granulating Wounds Following Mohs Micrographic Surgery
Postoperative Wound Haemorrhage
Primary: Frequency of Postoperative Hemorrhagic Complications — 0; 6 Participants — p=.028
Early Phase 1 N=11 EEG Characteristics in ECT
Electroconvulsive Therapy · Direct Current Electroencephalogram · Ketamine
Primary: Number of Participants Assessed for Clinical Efficacy of ECT — 11 Participants
Early Phase 1 N=13 Non-Opioid Pramipexole and Pain
Chronic Pain
Primary: Brief Pain Inventory Score — 8; 6.7 score on a scale
Early Phase 1 N=9 Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas
Pancreatic Cancer
Primary: Number of Patients With a Treatment-related Immunologic Effect — 6 Participants
Early Phase 1 N=8 Imaging Glutamate Release From Alcohol
Alcohol Drinking
Primary: Alcohol-induced Change in Receptor Availability — -9.1 percentage change of BP_ND
Early Phase 1 N=6 Single Dose ADME Study of [14C]-Rencofilstat in Healthy Male Subjects
NASH With Fibrosis
Primary: To Determine the Mass Balance Recovery After a Single Oral Dose of [14C]-Rencofilstat — 91 percentage of total radioactivity
Early Phase 1 N=7 Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib
Metastatic Breast Cancer
Primary: Progression-free Survival (PFS) — 4.131147; NA months
Early Phase 1 N=5 Nicotinamide Riboside in LVAD Recipients
Heart Failure，Congestive · Heart Failure New York Heart Association Class IV · Mitochondrial Alteration
Primary: Number of Participates Experiencing Treatment-Emergent Adverse Events (Safety and Tolerability) — 2 Participants
Early Phase 1 N=72 Developing a Mobile Method to Measure THC-induced Impairment
Measuring THC-induced Cognitive Impairment Using a Mobile Application
Primary: Simple Reaction Time — .365; .386; .396 Seconds
Early Phase 1 N=15 Chloroprocaine Lavage to Improve Outcomes Related to Operative Cesarean Delivery
Cesarean Section
Primary: Chloroprocaine Plasma Concentration at 1 Minute — 14.3; 7.5; 3.5 ng/ml
Early Phase 1 N=34 Topical Loperamide Gel for Pain Reduction During Repeat Finger Lancing
Pain
Primary: Pain - Numeric Rating Scale — 2.6; 2.5; 1.9; 4.2 units on a scale — p=0.8
Early Phase 1 N=44 Sensory Augmentation Methods in Stroke
Stroke
Primary: Percentage of Participants With Related or Serious Adverse Events — 1; 0 Participants — p=1